Introduction Disillusionment with the current trial methodology used to evaluate antiretroviral agents is growing among both physicians and patients. In the first 10 years of antiretroviral drug development there was a need to test treatment tactics, strategies, and available treatment markers against clinical endpoints. It has now been convincingly demonstrated that antiretroviral combination therapy prolongs life and extends the disease free period'-5 and that most benefits of these therapies are predicted by short term changes in two laboratory markers: CD4 cell count and plasma HIV RNA load.67 Improvements in our understanding of the pathogenesis of HIV disease and viral dynamics8 have provided both patients and physicians with a greater understanding of the tools used to monitor HIV and have enabled the establishment of a new path to our therapy goals. To provide maximal improvement in patient outcome (both length and quality of life) we must arrest the disease process, by blocking viral replication, and improve immune function, by enabling reexpansion of lost T lymphocyte populations. The availability of more potent antiretroviral combinations and of routine viral load measurement has enabled the establishment of an "undetectable" viral load as the optimum response to treatment. This response is typically associated with substantial delays in the selection of drug resistant viral mutants and, hence, is associated with more prolonged therapeutic responses than those observed with less complete suppression of viral replication. Measurement of CD4 and HIV RNA provides physicians with the opportunity to optimise the management of antiretroviral therapy. of results from < 5000 copies to over 1 000 000 copies. Because of the inaccuracies of the technique, it is preferable to refer to log units (for the values above the log unit equivalents are < 3-3 to > 6). The DELTA study,3 coordinated by the Medical Research Council, is looking at about 13 000 viral load tests and CD4 counts in about 2000 patients and will relate the results to clinical event rates. It is tempting to assume that CD4 counts will be a good marker of the degree of disease progression while the level of qRNA will be associated with the disease activity and therefore future disease progression.
qRNA has also been used to monitor short term changes in viral load following drug treatment. Zidovudine reduces plasma viral load RNA by about 0.3 log units and two drug combinations of reverse transcriptase inhibitors reduce viral load by up to 1.8 log units. However, the largest changes have been seen in triple therapy regimens which include HIV protease inhibitors. These combinations reduce qRNA by about 2.0 log units and in some cases qRNA falls to below the "limit of detection", which ranges from 10 000 copies (4.0 log units) to 20 copies (1.3 log units), according to the assay. The present enthusiasm for protease inhibitors depends much on the dramatic effect that these drugs have on the viral load.
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